Rabies deaths in Pakistan: results of ineffective post-exposure treatment.

[1]  S. Madhusudana,et al.  Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  S. Madhusudana,et al.  Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies. , 2001, The National medical journal of India.

[3]  Berni Dwan,et al.  Myths and facts , 2000 .

[4]  H. Wilde,et al.  A study of human rabies immune globulin manufactured by the Thai Red Cross. , 1999, Vaccine.

[5]  W. Haupt.  Rabies--risk of exposure and current trends in prevention of human cases. , 1999, Vaccine.

[6]  J. Milstien,et al.  Thermostability of vaccines. , 1999, Revista panamericana de salud publica = Pan American journal of public health.

[7]  S. Rishpon,et al.  [Prevention of human rabies]. , 1999, Harefuah.

[8]  S. Luby,et al.  Postexposure treatment of rabies in Pakistan. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Robert T. Chen,et al.  Vaccine safety: current and future challenges. , 1998, Pediatric annals.

[10]  T. John.  An ethical dilemma in rabies immunisation. , 1997, Vaccine.

[11]  P. Khawplod,et al.  Immune response to tissue culture rabies vaccine in subjects who had previous postexposure treatment with Semple or suckling mouse brain vaccine. , 1996, Vaccine.

[12]  V. Sitprija,et al.  Heterologous Antisera and Antivenins Are Essential Biologicals: Perspectives on a Worldwide Crisis , 1996, Annals of Internal Medicine.

[13]  H. Koprowski,et al.  Laboratory Techniques in Rabies , 2022 .

[14]  Chowdhury Ma,et al.  Neuroparalytic complications after anti-rabies vaccine (inactivated nervous tissue vaccine) , 1995 .

[15]  Fishbein Db,et al.  Rationale and prospects for rabies elimination in developing countries , 1994 .

[16]  F. Meslin,et al.  Rationale and prospects for rabies elimination in developing countries. , 1994, Current topics in microbiology and immunology.

[17]  Burney Mi.  Transferring manufacturing technology. Producing essential vaccines in Pakistan. , 1993 .

[18]  S. Arya.  Acquisition of spongiform encephalopathies in India through sheep-brain rabies vaccination , 1991, Indian journal of pediatrics.

[19]  M. Meltzer,et al.  Rabies control in the Republic of the Philippines: benefits and costs of elimination. , 1991, Vaccine.

[20]  S. Madhusudana,et al.  Reduction in the dosage schedule of BPL-inactivated neural tissue vaccine for rabies prophylaxis in man. , 1990, The Indian journal of medical research.

[21]  S. Chutivongse,et al.  Equine rabies immune globulin: a product with an undeserved poor reputation. , 1990, The American journal of tropical medicine and hygiene.

[22]  F. Yusuf,et al.  Demographic techniques. 3rd ed. , 1990 .

[23]  F. Lin.  The protective effect of the large-scale use of PHKC rabies vaccine in humans in China. , 1990, Bulletin of the World Health Organization.

[24]  Tang Ys.  Rabies in Malaysia. , 1988 .

[25]  Lin Fang-Tao,et al.  Use of Serum and Vaccine in Combination for Prophylaxis Following Exposure to Rabies , 1988 .

[26]  S. Halstead.  Tissue culture-based rabies vaccines: vaccine production technology transfer. , 1988, Reviews of infectious diseases.

[27]  S. Wattanasri,et al.  A high rate of neurological complications following Semple anti-rabies vaccine. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  Y. Wang,et al.  Use of serum and vaccine in combination for prophylaxis following exposure to rabies. , 1988, Reviews of infectious diseases.

[29]  S. Sirivichayakul,et al.  Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine. , 1987, Asian Pacific journal of allergy and immunology.

[30]  A. Moser,et al.  Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. , 1987, The New England journal of medicine.

[31]  A. Ogunkoya,et al.  Emergence of antirabies vaccine of unknown origin for human treatment in Nigeria. , 1986, Vaccine.

[32]  K. Bögel,et al.  Incidence of rabies and post-exposure treatment in developing countries. , 1986, Bulletin of the World Health Organization.

[33]  D. Warrell,et al.  ECONOMICAL MULTIPLE-SITE INTRADERMAL IMMUNISATION WITH HUMAN DIPLOID-CELL-STRAIN VACCINE IS EFFECTIVE FOR POST-EXPOSURE RABIES PROPHYLAXIS , 1985, The Lancet.

[34]  K. Nicholson,et al.  STABILITY OF HUMAN DIPLOID-CELL-STRAIN RABIES VACCINE AT HIGH AMBIENT TEMPERATURES , 1983, The Lancet.

[35]  H. Gruschkau,et al.  PURIFIED CHICKEN EMBRYO CELL RABIES VACCINE FOR HUMAN USE , 1983, The Lancet.

[36]  H. Meislin,et al.  Human rabies: 2016 updates and call for data. , 2017, Releve epidemiologique hebdomadaire.

[37]  H. Koprowski,et al.  Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. , 1976, JAMA.

[38]  M. Burney,et al.  The Rabies Problem in Pakistan , 1976, Tropical doctor.

[39]  R. Kalinowski.  TESTS FOR IMMIGRANT DOCTORS , 1975, The Lancet.

[40]  W. Quinton,et al.  PROLONGED PERITONEAL DIALYSIS FOR CHRONIC RENAL FAILURE. , 1964, Lancet.

[41]  N. Veeraraghavan,et al.  The value of 5 per cent Semple vaccine prepared in distilled water in human treatment: comparative mortality among the treated and untreated. , 1958, The Indian journal of medical research.

[42]  M. Baltazard,et al.  [Prevention of human rabies; treatment of the persons bitten by rabid wolves in Iran]. , 1953, Revue d'immunologie et de therapie antimicrobienne.